SNNLive spoke with James Killeffer, MD, FAANS, Chief Medical Officer of Arkis Biosciences at SEMDA 2014 Annual Conference in Atlanta, GA. “Arkis is a company that was formed to address the problem of hydrocephalus. Hydrocephalus is a buildup of fluid in the brain which is normally created but for whatever reason doesn’t drain down and get reabsorbed,” begins Dr. Killeffer. He continues, “The current treatments for hydrocephalus, for the most part consist of a mechanical device, a shunt that shunts fluid from the brain, under the skin into the abdomen where it gets reabsorbed. The problem with shunts is that they tend to fail, in fact probably 75% of shots require revision surgery over their lifetime.”
Dr. Killefer explains, “Our products decrease the rate of infection, decrease the incidence of obstruction and need for revision surgery and decrease the need for revision because of over drainage.” He adds, “I introduced this idea to my engineering friends because I hate shunts, because shunts incessantly need revision surgery and I hate going in the middle of the night and revising shunts.” SNNLive welcomes Dr. James Killeffer, Chief Medical Officer of Arkis Biosciences. For more information, check out their website at www.arkbiosciences.com.
© 2017 Stock News Now
Supported by Superior Web Solutions